Immatics (IMTX) Presents ESMO Data While Valuation Still Looks Pricey

Immatics (NasdaqCM:IMTX) put fresh clinical data in front of oncologists and investors at ESMO 2026, updating early stage results for its IMA402 bispecific and IMA203CD8 cell therapy in heavily pretreated solid tumor patients.

Against that clinical backdrop, Immatics shares tell a different story, with the 1 month share price return down 5.14% and the year to date share price return down 31.10%. This has contributed to a 1 year total shareholder return decline of 29.34% that signals fading momentum despite fresh data catalysts.

Scan beyond Immatics to compare clinical-stage oncology opportunities against a curated set of 19 high quality undiscovered gems with similar high-risk, high-reward profiles.

Immatics now trades after a sharp pullback while fresh trial data sits on the table. Does that combination still skew the risk reward toward buyers, or has the easy upside already been priced out?

Preferred Price-to-Sales Multiple of 21.1x: Is it justified?

Valuation for Immatics currently leans on revenue rather than earnings, because the business is loss making and not expected to reach profitability over the next three years. At a last close of $7.20, the stock trades on a P/S ratio of 21.1x, which matters far more than any earnings multiple right now.

P/S compares the value the market assigns to the equity with the revenue it generates. For a clinical stage biotech like Immatics, where products are still progressing through trials and reported net income is deeply negative at €206.549 million, investors often focus on this metric alongside pipeline quality and balance sheet strength.

The statement data flags that this 21.1x P/S is expensive compared with the broader US Biotechs industry on 11.3x. It is also described as expensive against an estimated fair P/S ratio of 0x, which points to a very wide gap between current pricing and a level the regression based fair ratio model could move toward.

At the same time, the same dataset indicates that Immatics looks better when held up against a closer peer set, where the average P/S is 24.6x. In that comparison, the stock is framed as good value, because investors are paying less per dollar of revenue than the peer group, even though losses have widened over the past five years and return on equity has been negative at 51.69%.

Result: Price-to-Sales of 21.1x (OVERVALUED)

Explore the SWS fair ratio for Immatics.

Still, the clinical story for Immatics can shift quickly if trial readouts disappoint or collaboration partners change priorities. This could challenge today’s rich P/S multiple.

Find out about the key risks to this Immatics narrative.

Next Steps

Mixed signals around Immatics can tempt you to lean heavily either way, but the better move is to pressure test the data yourself. Before you decide how to position, weigh the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Immatics?

Do not park your research on a single ticker. Broaden your watchlist with focused stock ideas that match different risk levels, income needs, and balance sheet preferences.

• Target potential upside with a carefully filtered group of underpriced businesses through the 33 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies in the 5 dividend fortresses that pair higher yields with staying power.
• Reduce portfolio shocks by scanning resilient candidates in the 29 resilient stocks with low risk scores before the crowd pays attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com